AMRX
Amneal Pharmaceuticals, Inc.
Key Financials
Operating Income
$394.1M
↑ 58.1%
Net Income
$72.1M
↑ 161.6%
Gross Profit
$1.1B
↑ 9.1%
Revenue
$3.0B
↑ 8.0%
EPS (Diluted)
$0.22
↑ 157.9%
Shareholders' Equity
$-70794000.00
↑ 35.2%
Total Liabilities
$0.00
N/A
Total Assets
$3.7B
↑ 5.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEFM14A | 6/29/2026 | View on SEC |
| PREM14A | 6/18/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 144 | 5/11/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
| 4 | 5/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AMRX |
| Company Name | Amneal Pharmaceuticals, Inc. |
| CIK | 1723128 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (908) 947-3120 |